文章：

打开SMARCA4缺陷未分化胸部肿瘤神秘宝箱的金钥匙：聚焦免疫疗法、肿瘤微环境与表观遗传调控

The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation

原文发布日期：2024-02-13 

英文摘要：

SMARCA4-deficient undifferentiated thoracic tumor is extremely invasive. This tumor with poor prognosis is easily confused with SMARCA4-deficent non-small cell lung cancer or sarcoma. Standard and efficient treatment has not been established. In this review, we summarized the etiology, pathogenesis and diagnosis, reviewed current and proposed innovative strategies for treatment and improving prognosis. Immunotherapy, targeting tumor microenvironment and epigenetic regulator have improved the prognosis of cancer patients. We summarized clinicopathological features and immunotherapy strategies and analyzed the progression-free survival (PFS) and overall survival (OS) of patients with SMARCA4-UT who received immune checkpoint inhibitors (ICIs). In addition, we proposed the feasibility of epigenetic regulation in the treatment of SMARCA4-UT. To our knowledge, this is the first review that aims to explore innovative strategies for targeting tumor microenvironment and epigenetic regulation and identify potential benefit population for immunotherapy to improve the prognosis. 

摘要翻译： 

SMARCA4缺陷型未分化胸腔肿瘤具有极高侵袭性。这种预后不良的肿瘤易与SMARCA4缺陷型非小细胞肺癌或肉瘤混淆，目前尚未建立标准有效的治疗方案。本文综述中，我们总结了该病的病因学、发病机制及诊断方法，回顾了当前及创新的治疗策略与改善预后的方案。免疫治疗、靶向肿瘤微环境和表观遗传调控等手段已显著改善癌症患者预后。我们系统归纳了SMARCA4-UT的临床病理特征和免疫治疗策略，分析了接受免疫检查点抑制剂（ICIs）治疗患者的无进展生存期（PFS）和总生存期（OS）。此外，我们首次探讨了表观遗传调控治疗SMARCA4-UT的可行性。据我们所知，这是首篇旨在探索靶向肿瘤微环境与表观遗传调控创新策略、并筛选免疫治疗潜在获益人群以改善预后的综述论文。

原文链接：

The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation